RecruitingNCT05332925

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (TUMORIN)

Sponsor

Jun Zhang, MD, PhD

Enrollment

25 participants

Start Date

Jul 21, 2022

Study Type

OBSERVATIONAL

Conditions

Lung Cancer NSCLC NSCLC Stage IV

Summary

To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.

Eligibility

Min Age: 18 YearsMax Age: 110 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting tumor tissue from patients with advanced non-small cell lung cancer (NSCLC) to grow miniature tumor models (tumoroids) in the lab, to see if these models can predict how well immunotherapy will work for each individual patient. **You may be eligible if...** - You are 18 or older with advanced or metastatic non-small cell lung cancer - You have not previously received immunotherapy - You have a tumor that can be safely biopsied - You are in reasonably good health (ECOG status 0–2) - You are scheduled to receive standard-of-care immunotherapy **You may NOT be eligible if...** - You are currently incarcerated - You are unable to make medical decisions or communicate effectively, as judged by your doctor Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.